Results 141 to 150 of about 578,179 (195)

UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies. [PDF]

J Hematol Oncol
Dell'Aversana C, Sgueglia G, Massaro C, Perricone U, Sarno F, Megchelenbrink WL, Conte M, Carafa V, Campanella A, Frenquelli M, Bordini J, Ghia P, Petrizzi VB, Alvarez R, Nappi D, Chiurazzi F, Tambaro FP, Wierda WG, de Lera AR, Altucci L.   +19 more
europepmc   +1 more source

Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton's tyrosine kinase inhibitor and bispecific antibody therapy. [PDF]

Front Oncol
Oura M, Toho M, Ikeda D, Fukuda N, Torres AS, Fujii F, Sakuma H, Uehara A, Tabata R, Narita K, Takeuchi M, Matsue K.   +11 more
europepmc   +1 more source

Covalent Bruton's tyrosine kinase inhibitor HZ-A-018 in patients with relapsed or refractory B cell malignancies: A multicenter phase I study. [PDF]

iScience
Wu G, Wei J, Yang H, Fan L, Yu S, Zhang J, Lin M, Zhou H, Xu N, Hu M, Zhou X, Jin J, Qian W, Shentu J.   +13 more
europepmc   +1 more source

Clinical Safety Profile of Bruton's Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukaemia: A Real-World Ambispective Study From India. [PDF]

Cureus
Pradhan A, Panchal HP.
europepmc   +1 more source

A pharmacovigilance study of Bruton's tyrosine kinase inhibitors: a multidimensional analysis based on FAERS and VigiBase. [PDF]

Front Immunol
Qu H, Jia Y, Liu Z, Li Z, Zhao X, Wu Z, Fan G, Lou Y.   +7 more
europepmc   +1 more source

Pharmacologic Inhibition of Bruton's Tyrosine Kinase Attenuates Experimental Abdominal Aortic Aneurysms

JVS - Vascular Science, 2020
Baohui Xu, Yankui Li, Gang Li, Yingbin Ge, Jia Guo, Weirong Fang, Wei Wang, Fanru Shen, Takahiro Shoji, Toru Ikezoe, Xiaoya Zheng, Sihai Zhao, Xiaofeng Chen, Masaaki Miyata, Alan Daugherty, Hong Lu, Ronald L. Dalman   +16 more
doaj   +1 more source

Next-generation Bruton's tyrosine kinase inhibitors for chronic lymphocytic leukemia-associated membranoproliferative glomerulonephritis: a case report. [PDF]

Ann Hematol
Chen L, Huang Y, Xu J, Huang S, Zhang Q, Hua F, Pan X, Mi JQ.   +7 more
europepmc   +1 more source

Current and future landscape of Bruton tyrosine kinase inhibitors in allergy. [PDF]

J Allergy Clin Immunol
Lin EV, Arce B, Alvarez-Arango S, Dispenza MC.   +3 more
europepmc   +1 more source

Cryptococcal Infection in a Patient With Chronic Lymphocytic Leukaemia Receiving Acalabrutinib, a Bruton's Tyrosine Kinase Inhibitor: A Case Report. [PDF]

Cureus
Al-Shaker AN, Agarwal A, Saeed MT, Marney Z.   +3 more
europepmc   +1 more source

Patterns of Bruton's Tyrosine Kinase Inhibitor (BTKi) Usage in B-cell Lymphomas in India: A Questionnaire-Based Study. [PDF]

Cureus
Naseem A, Pednekar A, Patil S, Barkate H.   +3 more
europepmc   +1 more source